Registry for Adults With Plasma Cell Disorders (PCD's)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Amyloidosis
- Castleman's Disease
- Cryoglobulinemia
- Heavy Chain Deposition Disease
- Light Chain Deposition Disease
- Multiple Myeloma
- Plasma Cell Leukemia
- Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes
- Smoldering Multiple Myeloma
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OBJECTIVES: Primary To create a Registry (to be called the PCD Registry) of PCD patients To have participating patients complete an assessment at enrollment and to repeat the assessment longitudinally over time. Secondary To gather information, including patterns of patient care, that would lend sup...
OBJECTIVES: Primary To create a Registry (to be called the PCD Registry) of PCD patients To have participating patients complete an assessment at enrollment and to repeat the assessment longitudinally over time. Secondary To gather information, including patterns of patient care, that would lend support for future research in the PCD population. Specific research questions would be explored within separate IRB-reviewed protocols. To bank blood samples for future research involving adults with PCD's, specifically examining p16INK4a and other markers to be specified in future, separate, IRB-approved protocols as specific research questions are identified. OUTLINE: Patients complete an assessment at baseline and then longitudinally over time which involves a multi-dimensional inter-disciplinary evaluation of a patient's functional status (ability to live independently at home and in the community), co-morbid medical conditions, cognition, psychological status, social functioning and support, medication review, and nutritional status. Patients' medical records are also reviewed.
Tracking Information
- NCT #
- NCT03717844
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Sascha Tuchman, MD UNC Lineberger Comprehensive Cancer Center